Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims (indication and mechanism) are supported by the provided label excerpts. Several dosing-related and adverse-effect claims are partially supported or not supported by the excerpts provided, and some statements are over-specific (“typically” for 25 mg/50 mg once nightly) without exact support from the supplied sections.
Category Scores
Accurate Statements
Quviviq (daridorexant) is a prescription medication used to treat insomnia in adults.
Section 1 INDICATIONS AND USAGE: “QUVIVIQ is indicated for the treatment of adult patients with insomnia…”
Quviviq works by blocking the action of orexin, a neurotransmitter that promotes wakefulness.
Section 12.1 Mechanism of Action: antagonism of orexin receptors; “Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.”
Unsupported Statements
Quviviq is typically prescribed in 25 mg doses taken orally once nightly.
Label excerpt provides a recommended dosage range (25 mg to 50 mg) and dosing conditions (oral, no more than once per night, within 30 minutes of going to bed, with at least 7 hours remaining). It does not support the phrasing that 25 mg is “typically” used or that it is the usual dosing for all patients.
Quviviq is typically prescribed in 50 mg doses taken orally once nightly.
Label excerpt provides that the recommended dosage range is 25 mg to 50 mg and limits dosing to no more than once per night. It does not support the phrasing that 50 mg is “typically” prescribed.
Common side effects of Quviviq may include somnolence, headache, and fatigue.
The provided label excerpts under Section 6 only list warnings/precautions topics and clinical trial experience context. They do not list somnolence, headache, or fatigue as common adverse reactions.
Contradictions
Important Omissions
For dosing, the label specifies timing/constraints: taken orally no more than once per night within 30 minutes of going to bed and with at least 7 hours remaining prior to planned awakening.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Indication and mechanism are label-supported. However, the dosing statements are over-generalized (“typically”) and omit key label dosing constraints, and the adverse-effect list is not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Over-specific/over-general claims about “typical” 25 mg and 50 mg dosing and an adverse-effect list that is not supported by the provided label excerpts.
Suggested Improvement
Rephrase dosing to match the label excerpt: “recommended dosage range is 25 mg to 50 mg taken orally no more than once per night within 30 minutes of going to bed, with at least 7 hours remaining prior to planned awakening,” and remove or support adverse reactions with the label section that lists them.